Kumenyezelwe Ucwaningo Olusha Lokugomela Ukwelapha Umdlavuza eShayina

A BAMBA MahhalaRelease 8 | eTurboNews | eTN
Isithombe sikaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

I-Innovent Biologics, Inc. (Innovent), inkampani ye-biopharmaceutical esezingeni lomhlaba ethuthukisa, ekhiqiza futhi ihwebe ngemithi esezingeni eliphezulu yokwelapha umdlavuza, i-metabolic, i-autoimmune nezinye izifo ezinkulu, kanye ne-NeoCura Bio-Medical Technology Co., Ltd. I-NeoCura), inkampani ehamba phambili enikwe amandla i-RNA esebenza ngokunemba kwemithi ye-biotech ezinikele ekwakhiweni kwenkundla yezidakamizwa esezingeni eliphezulu ye-RNA, namuhla imemezele ngokuhlanganyela ukuthi yenze isivumelwano sokusebenzisana sokwenza ucwaningo lomtholampilo e-China mayelana nokwelashwa okuhlangene kwe-sintilimab. kusukela kumgomo we-Innovent kanye neoantigen yomuntu ngamunye i-NEO_PLIN2101 evela ku-NeoCura.

U-Innovent uzosebenzisana ne-NeoCura e-China ukuhlola ukuphepha, i-pharmacokinetics, i-pharmacodynamics kanye nempumelelo yokuqala yokwelapha okuhlangene kusetshenziswa i-sintilimab evela ku-Innovent kanye ne-NEO_PLIN2101 evela ku-NeoCura ezigulini ezinomdlavuza, ukuze kuthuthukiswe ukuthuthukiswa komtholampilo kwe-immunotherapy ehlangene yezimila eziningi eziqinile futhi zilungiselele ukuhambisa. isicelo somuthi omusha wokuphenya (IND) ku-National Medical Products Administration (NMPA) maduze nje.

UDkt. Liu Yongjun, uMongameli we-Innovent, uthe: “Sihlabeke umxhwele ngepayipi le-R&D elihlukanisiwe le-NeoCura kanye nethimba labacwaningi bamazwe ngamazwe, futhi siyajabula ukungena kulokhu kubambisana okunesu lokuhlola ukubaluleka komtholampilo kwe-sintilimab kuhlanganiswe nemithi yokugomela i-neoantigen yezimila eziqinile. . I-Innovent inepayipi eliqinile elinamakhono aqinile ku-immunology kanye nebhayoloji yomdlavuza. Njengamanje, sinemithi emihlanu emisha egunyaziwe futhi yethulwa e-China futhi izoba nemithi emisha engaphezu kwe-10 ezokwethulwa eminyakeni emi-2-3 ezayo. Inkundla yethu edidiyelwe ngokugcwele iqongelele i-R&D eqinile, ukuthuthukiswa kwemitholampilo namandla okudayisa futhi ilungele ozakwethu ekhaya naphesheya. Sithemba futhi ukuqhubekisela phambili ukuhlola amathuba amasha ekwandiseni izinkomba kanye nokuthuthukisa ukusebenza ngempumelelo kokwelapha kwe-sintilimab ngokuhlanganiswa nezindlela zokwelapha ezintsha. Sibheke ngabomvu ukusebenzisana okubanzi nokujulile phakathi kwamaqembu amabili esikhathini esizayo. “

UDkt. Wang Yi, umsunguli we-NeoCura, wathi: “Okwamanje, imigomo ye-neoantigen iyindlela yokwelapha evelayo enenguquko emhlabeni wonke. I-NeoCura ibigxile ku-R&D yemithi yokugomela i-tumor neoantigen selokhu yasungulwa, ngethemba lokunqoba izinselelo ezikhona zokwelashwa kwamasosha omzimba ekwelapheni izimila eziqinile ngokusetshenziswa kobuchwepheshe obusha. Ukusebenzisana no-Innovent kuzodlala indima ehlangene yokugomela i-neoantigen yomuntu siqu kanye nezidakamizwa ze-monoclonal antibody futhi kuhlole ngokuhlanganyela umphumela womtholampilo wokwelapha okuhlangene ekwelapheni izimila eziqinile, okulindeleke ukuthi kuthuthukiswe izinga lokuphendula kwenhloso ye-immunotherapy futhi ilethe amathuba amasha. ngemithi ehlanganisa umdlavuza.”

Mayelana umbhali

Isithombe sikaLinda Hohnholz

Linda Hohnholz

Umhleli omkhulu we eTurboNews ezinze eTN HQ.

Bhalisa
Yazisa ngakho
isivakashi
0 Amazwana
Okungaphakathi Okuphakelayo
Buka wonke amazwana
0
Ungathanda imibono yakho, ngicela uphawule.x
Yabelana ku...